Akebia Therapeutics, Inc. (AKBA)
USD 1.76
(-5.88%)
USD 1.76
(-5.88%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -23.38 Million | -73.15 Million | -252.96 Million | -110.38 Million | -257.44 Million | -97.49 Million |
| Net Income | -51.92 Million | -92.56 Million | -282.84 Million | -383.45 Million | -279.65 Million | -143.58 Million |
| Depreciation & Amortization | 41.84 Million | 37.69 Million | 37.97 Million | 33.59 Million | 38.64 Million | 2.42 Million |
| Deferred income taxes | 6.79 Million | - | 36.57 Million | 204.07 Million | -6.63 Million | -28.33 Million |
| Stock-based compensation | 9.31 Million | 17.84 Million | 22.73 Million | 24.46 Million | 11.92 Million | 19.04 Million |
| Change in working capital | -20.72 Million | -1.43 Million | -108.41 Million | -13.67 Million | -99.06 Million | 36.01 Million |
| Other non-cash items | -8.68 Million | -34.7 Million | 41.01 Million | 24.61 Million | 77.34 Million | 16.95 Million |
| Investing Cash Flow | - | -114 Thousand | 39.94 Million | -40 Million | 211.17 Million | 36.59 Million |
| Investments in PPE | - | -114 Thousand | -59 Thousand | -317 Thousand | -6.65 Million | -1.6 Million |
| Acquisitions | - | - | - | 39.68 Million | - | 6.14 Million |
| Investment purchases | - | - | - | -99.93 Million | - | -224.21 Million |
| Sales/Maturities of investments | - | - | 40 Million | 60.24 Million | 217.83 Million | 256.26 Million |
| Other Investing Activities | - | - | 40 Million | -39.68 Million | 217.83 Million | 32.05 Million |
| Financing Cash Flow | -25.2 Million | 14.59 Million | 133.73 Million | 231.72 Million | 88.97 Million | 96.56 Million |
| Debt repayment | -32 Million | -33 Million | -44.78 Million | -19.97 Million | -15 Million | -19 Thousand |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | -426 Thousand | - |
| Common Stock Issuance | 6.79 Million | 7.12 Million | 88.2 Million | 209.41 Million | 25.78 Million | 96.58 Million |
| Other Financing Activities | -31.91 Million | 40.47 Million | 90.31 Million | 42.27 Million | 78.61 Million | 96.58 Million |
| Accounts receivables | 994 Thousand | 11.69 Million | -24.02 Million | 12.01 Million | -22.19 Million | 33.38 Million |
| Accounts payables | -5.24 Million | 1.5 Million | -11.73 Million | 3.67 Million | 1.37 Million | 13.71 Million |
| Inventory | -2.54 Million | 19.79 Million | -25.84 Million | 6.16 Million | -29.14 Million | 26 Thousand |
| Other working capital | -13.93 Million | -34.42 Million | -46.81 Million | -35.52 Million | -49.1 Million | -11.1 Million |
| Cash at beginning of period | 90.46 Million | 151.83 Million | 231.13 Million | 149.8 Million | 107.09 Million | 71.43 Million |
| Cash at end of period | 42.92 Million | 93.16 Million | 151.83 Million | 231.13 Million | 149.8 Million | 107.09 Million |
| Capital Expenditure | - | -114 Thousand | -59 Thousand | -317 Thousand | -6.65 Million | -1.6 Million |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | -47.54 Million | -58.67 Million | -79.29 Million | 81.32 Million | 42.7 Million | 35.66 Million |
| Free Cash Flow | -23.38 Million | -73.26 Million | -253.02 Million | -110.7 Million | -264.09 Million | -99.1 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -8.58 Million | -17.98 Million | -51.92 Million | 613 Thousand | -14.48 Million | -11.83 Million |
| Depreciation & Amortization | 9.41 Million | 9.37 Million | 41.84 Million | 9.4 Million | 9.4 Million | 9.4 Million |
| Deferred income taxes | - | - | 6.79 Million | -44.29 Million | 715 Thousand | 277 Thousand |
| Stock-based compensation | 2.07 Million | 2.36 Million | 9.31 Million | 1.51 Million | 1.82 Million | 3.49 Million |
| Change in working capital | -13.64 Million | -15.14 Million | -20.72 Million | -16.2 Million | -4.2 Million | 3.52 Million |
| Other non-cash items | 32.86 Million | 22.34 Million | -8.68 Million | 46.66 Million | -418 Thousand | -1.23 Million |
| Investing Cash Flow | -29 Thousand | - | - | - | - | - |
| Investments in PPE | -29 Thousand | - | - | - | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | -29 Thousand | - | - | - | - | - |
| Financing Cash Flow | 7.64 Million | 18.47 Million | -25.2 Million | -1.29 Million | 50 Thousand | -8 Million |
| Debt repayment | -7.62 Million | -274 Thousand | -32 Million | -8 Million | - | -8 Million |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | -750 Thousand | - | - | - | - |
| Common Stock Issuance | 14 Thousand | 18.95 Million | 6.79 Million | 6.71 Million | 50 Thousand | - |
| Other Financing Activities | 14 Thousand | -750 Thousand | -31.91 Million | 6.71 Million | 50 Thousand | -8 Million |
| Accounts receivables | -3.14 Million | 12.67 Million | 994 Thousand | -16.69 Million | -3.02 Million | -687 Thousand |
| Accounts payables | 6.77 Million | -7.5 Million | -5.24 Million | 4.5 Million | 2.31 Million | -3.04 Million |
| Inventory | -14.92 Million | -4.43 Million | -2.54 Million | -11.78 Million | -1.59 Million | 3.48 Million |
| Other working capital | -2.34 Million | -15.88 Million | -13.93 Million | 7.76 Million | -1.9 Million | 3.77 Million |
| Cash at beginning of period | 41.96 Million | 42.92 Million | 90.46 Million | 46.52 Million | 55.29 Million | 59.66 Million |
| Cash at end of period | 39.49 Million | 41.96 Million | 42.92 Million | 42.92 Million | 48.17 Million | 55.29 Million |
| Capital Expenditure | -29 Thousand | - | - | - | - | - |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | -2.46 Million | -964 Thousand | -47.54 Million | -3.6 Million | -7.11 Million | -4.37 Million |
| Free Cash Flow | -10.09 Million | -19.43 Million | -23.38 Million | -2.3 Million | -7.16 Million | 3.62 Million |
ALJXR
POAHY
3936
0LJB
AOLS
GENO